CU6ASXClarity Pharmaceuticals Ltd

CU6 price activity

Last Price

Change (24hr)

AUD (%)

Volume

Volume (4w avg)

Previous Close

N/A

Last Trade

CU6 price performance

-4.58%

6.38%

-26.04%

YTD

-28.16%

CU6 price fundamentals

N/A

Shares Issued

N/A

Earnings Per Share (EPS)

N/A

Dividends Per Share (DPS)

N/A

P/E Ratio

Price market cap

Market cap

N/A

AU-ASX rank

N/A

Sector Rank

N/A

CU6 details

View company profile

View company website

View AU-ASX Official Page

CU6 dividends

CU6 Market Signals

More ways to discover

Browse Australia news Discover ASX signals Browse all ASX stocks Browse all ASX ETFs

Clarity Pharmaceuticals Ltd (AU-ASX: CU6)

Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, engages in research and development of radiopharmaceuticals products for oncology in Australia and the United States. The company's lead product is SAR-bisPSMA, a theranostic radiopharmaceutical for the treatment of Prostate Specific Membrane Antigen (PSMA) cancer. It also develops SAR-Bombesin, a pan cancer theranostic radiopharmaceutical to treat prostate, breast, ovarian, urinary, small cell lung cancer, as well as glioblastoma and gastrointestinal stromal tumours; and SARTATE, a theranostic radiopharmaceutical for the treatment of somatostatin receptor 2 (SSTR2) cancer. The company was incorporated in 2010 and is based in Sydney, Australia.

Price: A$2.50

Sector: Healthcare — Biotechnology